Awareness of attention- deficit/hyperactivity disorder (ADHD) has increased over the past decade, yet drug treatment of this disorder remains controversial, particularly in Europe and Japan. Attention-Deficit/Hyperactivity Disorder is a new Decision Resources study that explains why drug sales for ADHD are relatively low despite the huge, potentially drug-treatable population and the availability of effective treatments in most regions. Analysts at Decision Resources find that new, long-acting reformulations of psychostimulants and the emergence of improved nonstimulant agents-combined with increased education efforts-promise to expand the ADHD market.
Numerous Companies Compete in the Growing Market for Long-Acting Psychostimulants
Numerous products will vie for leadership in the growing market for long- acting reformulations of existing psychostimulants; among them are Concerta (Alza), Metadate CD (Celltech Group), Adderall XR (Shire Pharmaceuticals), Ritalin-LA (Novartis/Celgene), and Methypatch (Noven). Considerable opportunity also exists for novel nonstimulants that prove to be as efficacious as psychostimulants.
Vast Opportunities Outside the United States
Although the United States represents only 42% of the prevalent ADHD population in the seven major markets, it accounts for approximately 97% of seven-market sales for this indication. This disproportion is the result of a greater awareness and acceptance of ADHD, a wider range of available treatment options, and a heavier reliance on drug therapy over behavioral therapy. Vast opportunities exist for pharmaceutical companies to expand their sales to the other six major markets.
Will the ADHD Market Reach Its Potential by 2010?
Overall, Decision Resources analysts anticipate healthy growth in the sales of ADHD therapies. We expect that psychostimulants will continue to dominate the market, led by long-acting formulations of methylphenidate. ADHD patients will also benefit from a growing number of emerging second-line therapies.
Attention-Deficit/Hyperactivity Disorder offers invaluable strategic intelligence for pharmaceutical companies competing in this market. This study is part of Mosaic, one of six Pharmacor services from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or firstname.lastname@example.org.
In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or email@example.com.
In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or firstname.lastname@example.org.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,